)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Jiangsu Nhwa Pharmaceutical
Jiangsu Nhwa Pharmaceutical (002262) investor relations material
Jiangsu Nhwa Pharmaceutical H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary18 Apr, 2026
Executive summary
Revenue reached ¥5.91 billion in 2025, up 3.75% year-over-year; net profit attributable to shareholders was ¥1.06 billion, down 7.54% from 2024.
Operating profit was ¥1.20 billion, down 10.28% year-over-year; cash flow from operations increased 17.71% to ¥1.08 billion.
R&D investment rose 20.52% to ¥869 million, with 70+ projects in the pipeline and 57 patent applications.
Dividend proposal: ¥4.00 per 10 shares, totaling ¥406 million, representing 38.43% of net profit.
Financial highlights
Gross margin for core products remained high: anesthetics 87.68%, psychiatric drugs 81.04%, neurology drugs 66.72%.
Total assets at year-end were ¥9.22 billion, up 9.28% from 2024; net assets attributable to shareholders rose 10.37% to ¥8.06 billion.
Basic and diluted EPS were both ¥1.05, down from ¥1.13 in 2024.
R&D expenses accounted for 14.7% of revenue.
Outlook and guidance
2026 focus: deepen CNS drug R&D, accelerate AI integration, and expand internationalization.
Plan to launch 1 innovative drug and 3 generic drugs, with 11 clinical projects and 1 consistency evaluation project expected.
Continued investment in digital transformation, cost control, and talent development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jiangsu Nhwa Pharmaceutical
- Revenue and net profit rose year-over-year, but operating cash flow declined sharply.002262
Q1 202618 Apr 2026 - Net profit up 11.38% year-over-year, with strong CNS drug sales and R&D growth.002262H1 202523 Dec 2025
- Q3 2025 revenue and net profit rose 5.70% and 3.67% year-over-year, respectively.002262Q3 202527 Oct 2025
- Q3 2024 saw double-digit revenue and profit growth, with robust cash flow and rising EPS.002262Q3 202413 Jun 2025
- H1 revenue and net profit rose 15%+ on CNS drug growth and robust R&D pipeline.002262H1 202413 Jun 2025
- 2024 revenue and net profit rose double digits, with strong CNS drug and digital health growth.002262H2 20249 Jun 2025
- Q1 2025 net profit up 13.35% year-over-year on strong sales and investment returns.002262Q1 20256 Jun 2025
Next Jiangsu Nhwa Pharmaceutical earnings date
Q2 202630 Jul, 2026
Jiangsu Nhwa Pharmaceutical
Next Jiangsu Nhwa Pharmaceutical earnings date
Q2 202630 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage